New depression pill shows promise in Late-Stage trial
NCT ID NCT06786624
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 22 times
Summary
This study tests whether adding NBI-1065845 to standard antidepressants can better relieve depression symptoms. About 200 adults with major depression who haven't fully responded to current meds will receive either the study drug or a placebo for 8 weeks. The main goal is to see if depression scores improve more with the new drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGLittle Rock, Arkansas, 72204, United States
-
Neurocrine Clinical Site
COMPLETEDGarden Grove, California, 92844, United States
-
Neurocrine Clinical Site
RECRUITINGOrange, California, 92866, United States
-
Neurocrine Clinical Site
RECRUITINGPico Rivera, California, 90660, United States
-
Neurocrine Clinical Site
RECRUITINGSan Diego, California, 92103, United States
-
Neurocrine Clinical Site
RECRUITINGUpland, California, 91786, United States
-
Neurocrine Clinical Site
RECRUITINGHollywood, Florida, 33024, United States
-
Neurocrine Clinical Site
RECRUITINGMaitland, Florida, 32751, United States
-
Neurocrine Clinical Site
RECRUITINGBoston, Massachusetts, 02116, United States
-
Neurocrine Clinical Site
SUSPENDEDWatertown, Massachusetts, 02472, United States
-
Neurocrine Clinical Site
RECRUITINGMount Kisco, New York, 10549, United States
-
Neurocrine Clinical Site
RECRUITINGAvon Lake, Ohio, 44012, United States
-
Neurocrine Clinical Site
COMPLETEDWestlake, Ohio, 44145, United States
-
Neurocrine Clinical Site
RECRUITINGDallas, Texas, 75251, United States
-
Neurocrine Clinical Site
RECRUITINGHouston, Texas, 77030, United States
-
Neurocrine Clinical Site
WITHDRAWNRichmond, Texas, 77407, United States
-
Neurocrine Clinical Site
SUSPENDEDThe Woodlands, Texas, 77381, United States
-
Neurocrine Clinical Site
RECRUITINGEverett, Washington, 98201, United States
Conditions
Explore the condition pages connected to this study.